Empagliflozin belongs to the class sodium-glucose cotransporter-2 inhibitors that improve the outcomes related to heart failure (HF). The underlying mechanisms are not well established, but diuretic properties of empagliflozin are speculated to positively affect outcomes. Compared to traditional diuretics, empagliflozin causes significant natriuresis by acting on the proximal tubule, improving blood volume. This favorable action can offer a substantial advantage in the management of volume status in patients with HF.1 In this regard, Boehringer Ingelheim India and Docplexus have organized a webinar with a renowned expert, Dr.
Faiez Zannad, to discuss the clinical development of empagliflozin in HF on 27th January 2022 at 03:00 PM. In this Q&A- based session, your questions will be addressed live by the expert. We look forward to an informative and enlightening discussion! References…